Arvinas ARVN Other programs — Program-specific external expense

Similar metrics at other companies

STOKOther External Program Costs — Operating Expenses

-$3.18M-73.8%

PRAXRelutrigine — Program-specific expenses

$13.98M+33.0%

PRAXUlixacaltamide — Program-specific expenses

$13.3M-27.7%

PRAXVormatrigine — Program-specific expenses

$12.88M-28.3%

PRAXElsunersen — Program-specific expenses

$8.14M+518%

NUV

NUVLDiscovery Programs — Direct Expenses Related To Program

$2.8M+31.4%

FAQ

What is Arvinas's other programs — program-specific external expense?

Arvinas (ARVN) reported other programs — program-specific external expense of $2.6M in Q1 2026.

How has Arvinas's other programs — program-specific external expense changed year-over-year?

Arvinas's other programs — program-specific external expense increased by 52.9% year-over-year, from $1.7M to $2.6M.

What is the long-term trend for Arvinas's other programs — program-specific external expense?

Over 3 years (2022 to 2025), Arvinas's other programs — program-specific external expense has grown at a 35.7% compound annual growth rate (CAGR), from $1.8M to $4.5M.

What does other programs — program-specific external expense mean?

This metric represents the direct external costs, such as clinical trial fees, contract research organization charges, and manufacturing expenses, specifically attributable to the company's secondary or exploratory research and development programs. It captures the capital allocation toward pipeline assets that are not categorized under the company's primary lead therapeutic candidates. Monitoring this spend provides insight into the company's investment strategy for diversifying its clinical portfolio and the pace of early-stage drug development.